- Drugging the NLRP3 inflammasome : from signalling mechanisms to therapeutic targets(2024)
Auteurs: Lieselotte Vande Walle, Mohamed Lamkanfi
Pagina's: 43 - 66
- Protein citrullination and NET formation do not contribute to the pathology of A20/TNFAIP3 mutant mice(2023)
Auteurs: Karel Van Damme, Pieter Hertens, Arne Martens, Elisabeth Gilis, Dario Priem, Inge Bruggeman, Amelie Fossoul, Jozefien Declercq, Helena Catharine Aegerter, Andy Wullaert, et al.
- Comment on : effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3(2023)
Auteurs: Lieselotte Vande Walle, Mohamed Lamkanfi
Pagina's: E166 - E167
- Nonredundancy of IL-1 alpha and IL-1 beta is defined by distinct regulation of tissues orchestrating resistance versus tolerance to infection(2022)
Auteurs: Kevin Eislmayr, Annika Bestehorn, Luisa Morelli, Martina Borroni, Lieselotte Vande Walle, Mohamed Lamkanfi, Pavel Kovarik
- GSDMD drives canonical inflammasome-induced neutrophil pyroptosis and is dispensable for NETosis(2022)
Auteurs: Dhruv Chauhan, Dieter Demon, Lieselotte Vande Walle, Oonagh Paerewijck, Annalisa Zecchin, Leslie Bosseler, Karin Santoni, Remi Planes, Sílvia Ribó Gené, Amelie Fossoul, et al.
- MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition(2019)
Auteurs: Lieselotte Vande Walle, Irma B Stowe, Pavel Sacha, Bettina L Lee, Dieter Demon, Amelie Fossoul, Filip Van Hauwermeiren, Pedro Henrique Viana Saavedra, Petr Simon, Vladimir Subrt, et al.
- The small GTPase Arf6 is essential for the Tram/Trif pathway in RLR4 signaling(2014)
Auteurs: Tim Van Acker, Lieselotte Vande Walle, Marc Goethals, Mohamed Lamkanfi, Celia Bovijn, Jan Tavernier
Pagina's: 1364 - 1376